Analyst 1 – Immunology

Accepting BioReady™: Yes
Category: Clinical Research
Education: Diploma/DEC
Location: Laval, QC
Posted: November 17, 2020
Closes: December 17, 2020

Job description:

For 70 years, Charles River employees have worked together to assist in the discovery, development and safe manufacture of new drug therapies. When you join our family, you will have a significant impact on the health and well-being of people across the globe. Whether your background is in life sciences, finance, IT, sales or another area, your skills will play an important role in the work we perform. In return, we’ll help you build a career that you can feel passionate about.

Job Summary

Performs technical laboratory activities in support of client studies or procedures. Performs analysis of data for quality and completeness and determines if results are as expected. Records data in compliance with company and regulatory policies and standards to meet quality and accuracy requirements.

We are seeking an Analyst I for our Immunology department site located in Laval (Greater Montreal area) in Canada.

The following are responsibilities related to the Analyst I:

  • Carry out sample analysis in a multidisciplinary laboratory, using a wide variety of techniques;
  • Prepare technical worksheets and procedures;
  • Receive, store, verify and process biological samples for analysis;
  • Take part in the routine duties of the laboratory such as preparation of reagents, instrument calibration, product reception;

The following are minimum qualifications related to the Analyst I position:

  • Collegial diploma in Science or B. Sc. degree in Biology or related field;
  • Knowledge of basic laboratory techniques and Immunology techniques such as ELISA;
  • Knowledge of flow cytometry, cell-based assays and molecular biology techniques (including QPCR) is an asset;
  • Reading and writing English is required. Bilingualism is preferable;
  • Ability to run experiments in an autonomous manner;

About Safety Assessment

Charles River is committed to helping our partners expedite their preclinical drug development with exceptional safety assessment services, state-of-the-art facilities and expert regulatory guidance. From individual specialty toxicology and IND enabling studies to tailored packages and total laboratory support, our deeply experienced team can design and execute programs that anticipate challenges and avoid roadblocks for a smooth, efficient journey to market.  Each year approximately 300 investigational new drug (IND) programs are conducted in our Safety Assessment facilities.

About Charles River

Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.

With over 17,000 employees within 90 facilities in 20 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges. Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2019, revenue increased to $2.62 billion.

At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~85% of the drugs approved by the FDA in 2019.

Apply Now